(Reuters) - Genzyme, which is developing the drug, Renvela, in a powder form as well as a tablet, said that the three-times-a-day powder version met the main goal of a trial designed to show it works as well as three doses a day of the company's kidney disease drug Renagel.
However, a trial testing one dose of powdered Renvela against three doses of Renagel tablets was not as effective and did not meet the trial's main goal.
Read more at Reuters.com Hot Stocks News
However, a trial testing one dose of powdered Renvela against three doses of Renagel tablets was not as effective and did not meet the trial's main goal.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment